AMGEN INC

Nasdaq:AMGN

Biological Products, (No Diagnostic Substances)·THOUSAND OAKS, CA

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.

CEO

Bradway Robert A

CFO

Griffith Peter H.

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	2/13/26	→
10-Q	Q3 2025	9/30/25	11/5/25	→
10-Q	Q2 2025	6/30/25	8/6/25	→
10-Q	Q1 2025	3/31/25	5/2/25	→
10-K	FY 2024	12/31/24	2/14/25	→
10-Q	Q3 2024	9/30/24	10/31/24	→
↓

Earnings Releases (8-K)

27 shown

Filed	Period
2/3/26	Q1 FY2026	→
11/4/25	Q4 FY2025	→
8/5/25	Q3 FY2025	→
5/1/25	Q2 FY2025	→
2/4/25	Q1 FY2025	→
10/30/24	Q3 FY2024	→
↓

News (8-K)

53 shown

Filed	Type	Description
2/19/26	Agreement	Entry into a Material Definitive Agreement	→
1/30/26	Other	Termination of a Material Definitive Agreement	→
5/27/25	Vote	Submission of Matters to a Vote of Security Holders	→
6/3/24	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/14/23	Exec Change	Departure or Appointment of Directors or Certain Officers	→
10/6/23	Acquisition	Completion of Acquisition or Disposition of Assets	→
↓

Prospectuses & Registrations

34 shown

Filed	Form	Description
2/19/26	424B2	424B2	→
2/17/26	FWP	FWP	→
2/17/26	424B3	424B3	→
2/13/26	S-3ASR	S-3ASR	→
4/2/25	ARS	ARS	→
6/12/24	S-8	S-8	→
↓

Filing History(1000 filings)

TypeDateAccessionPeriodSize

Mar 6, 2026

0000318154-26-000023PRIMARY DOCUMENT

Mar 4, 2026

10.0 KB

Mar 5, 2026

0000318154-26-000022PRIMARY DOCUMENT

Mar 3, 2026

5.6 KB

Mar 5, 2026

0000318154-26-000021PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 5, 2026

0000318154-26-000020PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 5, 2026

0000318154-26-000019PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 5, 2026

0000318154-26-000018PRIMARY DOCUMENT

Mar 3, 2026

5.6 KB

Mar 5, 2026

0000318154-26-000017PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 5, 2026

0000318154-26-000016PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 5, 2026

0000318154-26-000015PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 5, 2026

0000318154-26-000014PRIMARY DOCUMENT

Mar 3, 2026

6.2 KB

Mar 5, 2026

0000318154-26-000013PRIMARY DOCUMENT

Mar 3, 2026

4.7 KB

Mar 2, 2026

0000318154-26-000012PRIMARY DOCUMENT

Feb 26, 2026

14.5 KB

144

Feb 27, 2026

0000926544-26-000005

—

4.6 KB

25-NSE

Feb 24, 2026

0001354457-26-000212

—

3.0 KB

Feb 20, 2026

0000318154-26-000011PRIMARY DOCUMENT

Feb 19, 2026

4.7 KB

8-K

Feb 19, 2026

0001193125-26-0594908-K

Feb 17, 2026

642.4 KB

144

Feb 19, 2026

0001959173-26-001233

—

9.4 KB

424B2

Feb 19, 2026

0001193125-26-057840424B2

—

741.1 KB

FWP

Feb 17, 2026

0001193125-26-055091FWP

—

23.4 KB

424B3

Feb 17, 2026

0001193125-26-053192424B3

—

571.0 KB

S-3ASR

Feb 13, 2026

0001193125-26-051627S-3ASR

—

504.1 KB

10-K

Feb 13, 2026

0000318154-26-00001010-K

Dec 31, 2025

19.4 MB

Feb 10, 2026

0000318154-26-000006PRIMARY DOCUMENT

Feb 9, 2026

6.1 KB

8-K

Feb 3, 2026

0000318154-26-0000038-K

Feb 3, 2026

985.4 KB

8-K

Jan 30, 2026

0001193125-26-0305188-K

Jan 30, 2026

226.5 KB

25 filings shown

Filed	Form	Description
4/29/25	DEFA14A	DEFA14A	→
4/17/25	DEFA14A	DEFA14A	→
4/9/25	DEFA14A	DEFA14A	→
4/9/25	DEF 14A	DEF 14A	→
5/10/24	DEFA14A	DEFA14A	→
5/3/24	DEFA14A	DEFA14A	→
↓

AMGEN INC

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(1000 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/6/26	4	PRIMARY DOCUMENT	→
3/5/26	4	PRIMARY DOCUMENT	→
3/5/26	4	PRIMARY DOCUMENT	→
3/5/26	4	PRIMARY DOCUMENT	→
3/5/26	4	PRIMARY DOCUMENT	→
3/5/26	4	PRIMARY DOCUMENT	→
↓

Filed	Form	Description
2/27/26	144	144	→
2/24/26	25-NSE	25-NSE	→
2/19/26	144	144	→
11/20/25	144	144	→
11/12/25	144	144	→
11/12/25	144	144	→
↓